Initial Real-World Evidence for Lecanemab in the United States
Lecanemab utilization followed US FDA-approved prescribing information. Disparities for minority and rural-based populations were observed suggesting opportunities to improve access for underserved populations.
Authors
- Chenyue Zhao
- Feride Frech (ORCID: https://orcid.org/0000-0002-1992-1112)
- Diana I Brixner (ORCID: https://orcid.org/0000-0001-6637-6359)
- Michael Rosenbloom (ORCID: https://orcid.org/0000-0002-2768-9501)
- Hideki Toyosaki
Institutions
- University of Washington (US)
- University of Utah (US)
- Eisai (United States) (US)
- Eisai (Japan) (JP)
Publication Details
- Journal
- Drugs & Aging
- Published
- 2025-10-29
- DOI
- https://doi.org/10.1007/s40266-025-01261-x
- Citations
- 1
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 1.05
Funders
- Eisai